Kellerhals Carrard advises new investor Neva SGR on Nouscom’s series D

Kellerhals Carrard and Hogan Lovells Cadwalader advised Neva SGR on its entry as a new investor in the USD 135 million Series D financing round of Nouscom. The Swiss biotech will use the proceeds to advance NOUS-209 toward a global clinical trial intended to generate the evidence needed for potential registration.

Deal details

Neva SGR joined the round as a new investor. Its legal advisers were Kellerhals Carrard and Hogan Lovells Cadwalader, with support from the in-house legal team of Intesa Sanpaolo Group, made up of Massimiliano Canelli and Marta Cubisino.

M Ventures and Revelation Partners co-led the round. Other new investors were Angelini Industries, through Angelini Investments, and the European Investment Bank, through Aurea, its co-investment facility with Angelini Ventures.

Existing investors 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance (through its InnoBio2 fund), CDP Venture Capital (through its Large Ventures Fund), EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures and XGEN Ventures also participated.

The Kellerhals Carrard team

The core Kellerhals Carrard team was led by Luana Stämpfli (pictured), partner in Corporate/VC. She was supported by Marine Jorio, associate in Corporate/VC, Céline Schmid, counsel in employment, and Vera Vallone, senior associate in IP.